HERTFORDSHIRE, England and
PITTSBURGH, Jan. 6, 2020 /PRNewswire/ -- Global
pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced
that Chairman Robert J. Coury,
together with Upjohn's Group President Michael Goettler and Mylan's President
Rajiv Malik, will present at the
38th Annual J.P. Morgan Healthcare Conference in
San Francisco, Calif., on
Wednesday, Jan. 15, 2020 at
8:30 a.m. PT / 11:30 a.m. ET. Coury, Goettler and Malik
will serve as future executive chairman, chief executive officer
and president of Viatris, respectively.
Interested parties can access a live webcast of the presentation
via the investor relations section of Mylan's website at
investor.mylan.com. An archived version also will be available
following the live presentation and can be accessed at the same
location for a limited time.
Mylan is a global pharmaceutical company committed to setting
new standards in healthcare. Working together around the world to
provide 7 billion people access to high quality medicine, we
innovate to satisfy unmet needs; make reliability and service
excellence a habit; do what's right, not what's easy; and impact
the future through passionate global leadership. We offer a growing
portfolio of more than 7,500 marketed products around the world,
including antiretroviral therapies on which approximately 40% of
people being treated for HIV/AIDS globally depend. We market our
products in more than 165 countries and territories. We are one of
the world's largest producers of active pharmaceutical ingredients.
Every member of our approximately 35,000-strong workforce is
dedicated to creating better health for a better world, one person
at a time. Learn more at Mylan.com. We routinely post information
that may be important to investors on our website at
investor.mylan.com.
Forward-Looking Statements
This communication contains
"forward-looking statements". Such forward-looking statements may
include, without limitation, statements about the proposed
combination of Upjohn Inc. ("Newco") and Mylan N.V. ("Mylan"),
which will immediately follow the proposed separation of the Upjohn
business (the "Upjohn Business") from Pfizer Inc. ("Pfizer") (the
"proposed transaction"), the expected timetable for completing the
proposed transaction, the benefits and synergies of the proposed
transaction, future opportunities for the combined company and
products and any other statements regarding Pfizer's, Mylan's, the
Upjohn Business's or the combined company's future operations,
financial or operating results, capital allocation, dividend
policy, debt ratio, anticipated business levels, future earnings,
planned activities, anticipated growth, market opportunities,
strategies, competitions, and other expectations and targets for
future periods. Forward-looking statements may often be identified
by the use of words such as "will", "may", "could", "should",
"would", "project", "believe", "anticipate", "expect", "plan",
"estimate", "forecast", "potential", "pipeline", "intend",
"continue", "target", "seek" and variations of these words or
comparable words. Because forward-looking statements inherently
involve risks and uncertainties, actual future results may differ
materially from those expressed or implied by such forward-looking
statements. Factors that could cause or contribute to such
differences include, but are not limited to: the parties' ability
to meet expectations regarding the timing, completion and
accounting and tax treatments of the proposed transaction; changes
in relevant tax and other laws; the parties' ability to consummate
the proposed transaction; the conditions to the completion of the
proposed transaction, including receipt of approval of Mylan's
shareholders, not being satisfied or waived on the anticipated
timeframe or at all; the regulatory approvals required for the
proposed transaction not being obtained on the terms expected or on
the anticipated schedule or at all; inherent uncertainties involved
in the estimates and judgments used in the preparation of financial
statements and the providing of estimates of financial measures, in
accordance with accounting principles generally accepted in
the United States of America and
related standards or on an adjusted basis; the integration of Mylan
and Newco being more difficult, time consuming or costly than
expected; Mylan's, the Upjohn Business's and the combined company's
failure to achieve expected or targeted future financial and
operating performance and results; the possibility that the
combined company may be unable to achieve expected benefits,
synergies and operating efficiencies in connection with the
proposed transaction within the expected time frames or at all or
to successfully integrate Mylan and Newco; customer loss and
business disruption being greater than expected following the
proposed transaction; the retention of key employees being more
difficult following the proposed transaction; any regulatory, legal
or other impediments to Mylan's, the Upjohn Business's or the
combined company's ability to bring new products to market,
including but not limited to where Mylan, the Upjohn Business or
the combined company uses its business judgment and decides to
manufacture, market and/or sell products, directly or through third
parties, notwithstanding the fact that allegations of patent
infringement(s) have not been finally resolved by the courts (i.e.,
an "at-risk launch"); success of clinical trials and Mylan's, the
Upjohn Business's or the combined company's ability to execute on
new product opportunities; any changes in or difficulties with
Mylan's, the Upjohn Business's or the combined company's
manufacturing facilities, including with respect to remediation and
restructuring activities, supply chain or inventory or the ability
to meet anticipated demand; the scope, timing and outcome of any
ongoing legal proceedings, including government investigations, and
the impact of any such proceedings on Mylan's, the Upjohn
Business's or the combined company's consolidated financial
condition, results of operations and/or cash flows; Mylan's, the
Upjohn Business's and the combined company's ability to protect
their respective intellectual property and preserve their
respective intellectual property rights; the effect of any changes
in customer and supplier relationships and customer purchasing
patterns; the ability to attract and retain key personnel; changes
in third-party relationships; actions and decisions of healthcare
and pharmaceutical regulators; the impacts of competition; changes
in the economic and financial conditions of the Upjohn Business or
the business of Mylan or the combined company; uncertainties
regarding future demand, pricing and reimbursement for our, the
Upjohn Business's or the combined company's products; and
uncertainties and matters beyond the control of management and
other factors described under "Risk Factors" in each of Pfizer's
and Mylan's Annual Reports on Form 10-K, Quarterly Reports on Form
10-Q and other filings with the Securities and Exchange Commission
("SEC"). These risks, as well as other risks associated with Mylan,
the Upjohn Business, the combined company and the proposed
transaction are also more fully discussed in the Registration
Statement on Form S-4 which includes a proxy statement/prospectus
(as amended, the "Form S-4"), and Form 10 which includes an
information statement (as amended, the "Form 10"), each of which
has been filed by Newco with the SEC on October 25, 2019 and subsequently amended, and
has not yet been declared effective. You can access Pfizer's,
Mylan's and Newco's filings with the SEC through the SEC website at
www.sec.gov or through Pfizer's or Mylan's website, as applicable,
and Pfizer and Mylan strongly encourage you to do so. Except as
required by applicable law, Pfizer, Mylan and Newco undertake no
obligation to update any statements herein for revisions or changes
after the communications on this website are made.
Additional Information and Where to Find It
This
communication shall not constitute an offer to sell or the
solicitation of an offer to sell or the solicitation of an offer to
buy any securities, nor shall there be any sale of securities in
any jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the
securities laws of any such jurisdiction. No offer of securities
shall be made except by means of a prospectus meeting the
requirements of Section 10 of the Securities Act of 1933, as
amended. In connection with the proposed transaction, Newco and
Mylan have filed certain materials with the SEC, including, among
other materials, the Form S-4 and Form 10 filed by Newco. The
registration statements have not yet become effective. After
the Form S-4 is effective, a definitive proxy statement/prospectus
will be sent to the Mylan shareholders seeking approval of the
proposed transaction, and after the Form 10 is effective, a
definitive information statement will be made available to the
Pfizer stockholders relating to the proposed transaction.
Newco and Mylan intend to file additional relevant materials with
the SEC in connection with the proposed transaction, including a
proxy statement of Mylan in definitive form. INVESTORS AND
SECURITY HOLDERS ARE URGED TO READ DOCUMENTS FILED WITH THE SEC
CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY WILL CONTAIN IMPORTANT
INFORMATION ABOUT MYLAN, NEWCO AND THE PROPOSED TRANSACTION. The
documents relating to the proposed transaction (when they are
available) can be obtained free of charge from the SEC's website at
www.sec.gov. These documents (when they are available) can also be
obtained free of charge from Mylan, upon written request to Mylan,
at (724) 514-1813 or investor.relations@mylan.com or from Pfizer on
Pfizer's internet website at
https://investors.Pfizer.com/financials/sec-filings/default.aspx or
by contacting Pfizer's Investor Relations Department at (212)
733-2323, as applicable.
Participants in the Solicitation
This communication is
not a solicitation of a proxy from any investor or security holder.
However, Pfizer, Mylan, Newco and certain of their respective
directors and executive officers may be deemed to be participants
in the solicitation of proxies in connection with the proposed
transaction under the rules of the SEC. Information about the
directors and executive officers of Pfizer may be found in its
Annual Report on Form 10-K filed with the SEC on February 28, 2019 and its definitive proxy
statement and additional proxy statement relating to its 2019
Annual Meeting filed with the SEC on March
14, 2019 and on April 2, 2019,
respectively, and Current Report on Form 8-K filed with the SEC on
June 27, 2019. Information about the
directors and executive officers of Mylan may be found in its
amended Annual Report on Form 10-K filed with the SEC on
April 30, 2019, and its definitive
proxy statement relating to its 2019 Annual Meeting filed with the
SEC on May 24, 2019. Additional
information regarding the interests of these participants can also
be found in the Form S-4 and will also be included in the
definitive proxy statement of Mylan in connection with the proposed
transaction when it becomes available. These documents (when
they are available) can be obtained free of charge from the sources
indicated above.
View original
content:http://www.prnewswire.com/news-releases/mylan-to-present-at-the-38th-annual-jp-morgan-healthcare-conference-300981410.html
SOURCE Mylan N.V.